Hutch News

Stories tagged 'Philip D Greenberg'

Immunotherapy for ovarian cancer shows promise in mouse model, but hurdles remain

‘Tumor microenvironment’ poses unique challenges for T-cell therapy in solid tumors

April 4, 2017 | By Rachel Tompa / Fred Hutch News Service

A major roadblock to adopting T-cell therapy to solid tumors is what’s known as the tumor microenvironment, the local milieu of non-cancerous cells and molecules in and around the tumor. Fred Hutch researcher Dr. Kristin Anderson and her colleagues in Dr. Phil Greenberg's lab are working to overcome those barriers.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

March 31, 2017

Dr. Philip Greenberg elected to serve on AACR board of directors; five researchers receive awards to explore immunotherapy single-cell RNA sequencing.

View story >


A Q&A with Fred Hutch postdoctoral research fellow Dr. Rachel Perret

As part of a world-class immunotherapy research team, Perret is working her ‘dream job’ — trying to bring T-cell therapy to all who need it

Jan. 9, 2017 | By Rachel Tompa / Fred Hutch News Service

A postdoctoral research fellow training under the mentorship of immunotherapy expert Dr. Phil Greenberg, Dr. Rachel Perret is working toward an “off-the-shelf” version of T-cell therapy.

View story >


‘A place where miracles happen’: Opening of Bezos Family Immunotherapy Clinic highlights patient-focused science

Research symposium and ribbon cutting celebrates first-of-its-kind facility for experimental immunotherapies

Dec. 16, 2016 | By Susan Keown / Fred Hutch News Service

Lymphoma survivor Stephanie Florence said she wouldn't be alive if not for the science done at Fred Hutchinson Cancer Research Center. This week, she cut the ribbon at the grand opening of the Bezos Family Immunotherapy Clinic, which will make it possible for twice as many patients like Florence to receive treatment.

View story >


Immunotherapy shows promise in preventing leukemia relapse

Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years

Dec. 5, 2016 | By Susan Keown / Fred Hutch News Service

For patients with high-risk acute myeloid leukemia, relapse after bone marrow transplant signals a low chance of survival. But results from a small trial of genetically engineered immune cells show promise for keeping these patients out of danger: Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.

View story >


Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

Dec. 3, 2016 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.